Generali Investments Management Co LLC Grows Position in Amgen Inc. $AMGN

Generali Investments Management Co LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 23.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,663 shares of the medical research company’s stock after purchasing an additional 1,471 shares during the quarter. Generali Investments Management Co LLC’s holdings in Amgen were worth $2,162,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Andra AP fonden grew its position in Amgen by 306.9% during the 3rd quarter. Andra AP fonden now owns 47,200 shares of the medical research company’s stock worth $13,320,000 after purchasing an additional 35,600 shares during the last quarter. Hikari Tsushin Inc. acquired a new stake in shares of Amgen during the 3rd quarter valued at about $66,000. TIAA Trust National Association grew its position in shares of Amgen by 1.1% during the 3rd quarter. TIAA Trust National Association now owns 43,852 shares of the medical research company’s stock valued at $12,373,000 after acquiring an additional 492 shares during the period. Sumitomo Mitsui Financial Group Inc. increased its stake in shares of Amgen by 7.8% in the 3rd quarter. Sumitomo Mitsui Financial Group Inc. now owns 75,779 shares of the medical research company’s stock valued at $21,385,000 after purchasing an additional 5,457 shares in the last quarter. Finally, Banco Santander S.A. raised its holdings in Amgen by 5.8% in the 3rd quarter. Banco Santander S.A. now owns 20,053 shares of the medical research company’s stock worth $5,659,000 after purchasing an additional 1,102 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen hit an all-time intraday high, reflecting strong investor demand and momentum that likely supported upward price pressure earlier in the session. Amgen stock hits all-time high
• Positive Sentiment: Amgen is featured in dividend-stock roundup articles, which can attract long-term income-focused buyers and support demand for shares given its yield and payout profile. Got $10,000? Put It in These Dividend Stocks Now
• Neutral Sentiment: Commentary pieces note Amgen has outpaced the Dow over the past year, providing a positive performance backdrop — but analysts remain cautious, suggesting upside may be tempered by valuation and execution risks. Is Amgen Stock Outperforming the Dow?
• Neutral Sentiment: Legislative risk: S.3847 (Stop Corporate Inversions Act of 2026) was flagged as potentially relevant to multinationals including AMGN; the bill would tighten rules around inversion tax treatment — a longer-term policy item to monitor but not an immediate earnings driver. Stop Corporate Inversions Act of 2026
• Neutral Sentiment: Reported spikes in short interest appear in the feed but show zero shares/NaN in the figures — this looks like a data or reporting error rather than a meaningful change in positioning; still worth checking official exchange short-interest releases for confirmation.
• Negative Sentiment: A small institutional holder (Bradley Foster & Sargent) trimmed its position (~1,336 shares), a minor selling signal that may slightly contribute to sell-side flow but is not materially large versus Amgen’s market cap and average volume. Bradley Foster & Sargent Inc. CT Sells 1,336 Shares

Analysts Set New Price Targets

A number of analysts have recently commented on AMGN shares. BMO Capital Markets boosted their price objective on Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. DZ Bank boosted their price target on shares of Amgen from $335.00 to $364.00 in a report on Monday, November 10th. Royal Bank Of Canada upped their price objective on shares of Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th. Rothschild & Co Redburn lifted their target price on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research report on Wednesday, February 18th. Finally, Wells Fargo & Company boosted their target price on shares of Amgen from $325.00 to $375.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $351.76.

Amgen Stock Down 1.3%

NASDAQ AMGN opened at $379.33 on Friday. The business’s fifty day simple moving average is $347.68 and its 200-day simple moving average is $318.76. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The firm has a market cap of $204.48 billion, a PE ratio of 26.66, a P/E/G ratio of 3.81 and a beta of 0.46. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $387.49.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the firm earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.